SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
Background: Diffuse gliomas, grades II and III, hereafter called lower-grade gliomas (LGG), have variable, difficult to predict clinical courses, resulting in multiple studies to identify prognostic biomarkers. The purpose of this study was to assess expression or methylation of the homeobox family...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-11-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396416305011 |
| _version_ | 1818990088751677440 |
|---|---|
| author | Yu-An Zhang Yunyun Zhou Xin Luo Kai Song Xiaotu Ma Adwait Sathe Luc Girard Guanghua Xiao Adi F Gazdar |
| author_facet | Yu-An Zhang Yunyun Zhou Xin Luo Kai Song Xiaotu Ma Adwait Sathe Luc Girard Guanghua Xiao Adi F Gazdar |
| author_sort | Yu-An Zhang |
| collection | DOAJ |
| description | Background: Diffuse gliomas, grades II and III, hereafter called lower-grade gliomas (LGG), have variable, difficult to predict clinical courses, resulting in multiple studies to identify prognostic biomarkers. The purpose of this study was to assess expression or methylation of the homeobox family gene SHOX2 as independent markers for LGG survival.
Methods: We downloaded publically available glioma datasets for gene expression and methylation. The Cancer Genome Atlas (TCGA) (LGG, n = 516) was used as a training set, and three other expression datasets (n = 308) and three other methylation datasets (n = 320), were used for validation. We performed Kaplan-Meier survival curves and univariate and multivariate Cox regression model analyses.
Findings: SHOX2 expression and gene body methylation varied among LGG patients and highly significantly predicted poor overall survival. While they were tightly correlated, SHOX2 expression appeared more potent as a prognostic marker and was used for most further studies. The SHOX2 prognostic roles were maintained after analyses by histology subtypes or tumor grade. We found that the combination of SHOX2 expression and IDH genotype status identified a subset of LGG patients with IDH wild-type (IDHwt) and low SHOX2 expression with considerably favorable survival. We further investigated the combination of SHOX2 with other known clinically relevant markers of LGG (TERT expression, 1p/19q chromosome co-deletion, MGMT methylation, ATRX mutation and NES expression). When combined with SHOX2 expression, we identified subsets of LGG patients with significantly favorable survival outcomes, especially in the subgroup with worse prognosis for each individual marker. Finally, multivariate analysis demonstrated that SHOX2 was a potent independent survival marker.
Interpretation: We have identified that SHOX2 expression or methylation are potent independent prognostic indicators for predicting LGG patient survival, and have potential to identify an important subset of LGG patients with IDHwt status with significantly better overall survival. The combination of IDH or other relevant markers with SHOX2 identified LGG subsets with significantly different survival outcomes, and further understanding of these subsets may benefit therapeutic target identification and therapy selections for glioma patients. |
| first_indexed | 2024-12-20T19:48:49Z |
| format | Article |
| id | doaj.art-99837c923a7a4dc09bde37908d2c6bb6 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-20T19:48:49Z |
| publishDate | 2016-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-99837c923a7a4dc09bde37908d2c6bb62022-12-21T19:28:21ZengElsevierEBioMedicine2352-39642016-11-0113C808910.1016/j.ebiom.2016.10.040SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse GliomasYu-An Zhang0Yunyun Zhou1Xin Luo2Kai Song3Xiaotu Ma4Adwait Sathe5Luc Girard6Guanghua Xiao7Adi F Gazdar8The Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USADepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USADepartment of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USASchool of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, ChinaDepartment of Computational Biology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, USAThe Center for Systems Biology, Department of Molecular and Cell Biology, The University of Texas at Dallas, Richardson, TX, 75080, USAThe Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USADepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USAThe Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USABackground: Diffuse gliomas, grades II and III, hereafter called lower-grade gliomas (LGG), have variable, difficult to predict clinical courses, resulting in multiple studies to identify prognostic biomarkers. The purpose of this study was to assess expression or methylation of the homeobox family gene SHOX2 as independent markers for LGG survival. Methods: We downloaded publically available glioma datasets for gene expression and methylation. The Cancer Genome Atlas (TCGA) (LGG, n = 516) was used as a training set, and three other expression datasets (n = 308) and three other methylation datasets (n = 320), were used for validation. We performed Kaplan-Meier survival curves and univariate and multivariate Cox regression model analyses. Findings: SHOX2 expression and gene body methylation varied among LGG patients and highly significantly predicted poor overall survival. While they were tightly correlated, SHOX2 expression appeared more potent as a prognostic marker and was used for most further studies. The SHOX2 prognostic roles were maintained after analyses by histology subtypes or tumor grade. We found that the combination of SHOX2 expression and IDH genotype status identified a subset of LGG patients with IDH wild-type (IDHwt) and low SHOX2 expression with considerably favorable survival. We further investigated the combination of SHOX2 with other known clinically relevant markers of LGG (TERT expression, 1p/19q chromosome co-deletion, MGMT methylation, ATRX mutation and NES expression). When combined with SHOX2 expression, we identified subsets of LGG patients with significantly favorable survival outcomes, especially in the subgroup with worse prognosis for each individual marker. Finally, multivariate analysis demonstrated that SHOX2 was a potent independent survival marker. Interpretation: We have identified that SHOX2 expression or methylation are potent independent prognostic indicators for predicting LGG patient survival, and have potential to identify an important subset of LGG patients with IDHwt status with significantly better overall survival. The combination of IDH or other relevant markers with SHOX2 identified LGG subsets with significantly different survival outcomes, and further understanding of these subsets may benefit therapeutic target identification and therapy selections for glioma patients.http://www.sciencedirect.com/science/article/pii/S2352396416305011GliomasAstrocytomasOligodendrogliomasSHOX2 biomarkerIDH mutationPrognosis |
| spellingShingle | Yu-An Zhang Yunyun Zhou Xin Luo Kai Song Xiaotu Ma Adwait Sathe Luc Girard Guanghua Xiao Adi F Gazdar SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas EBioMedicine Gliomas Astrocytomas Oligodendrogliomas SHOX2 biomarker IDH mutation Prognosis |
| title | SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas |
| title_full | SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas |
| title_fullStr | SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas |
| title_full_unstemmed | SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas |
| title_short | SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas |
| title_sort | shox2 is a potent independent biomarker to predict survival of who grade ii iii diffuse gliomas |
| topic | Gliomas Astrocytomas Oligodendrogliomas SHOX2 biomarker IDH mutation Prognosis |
| url | http://www.sciencedirect.com/science/article/pii/S2352396416305011 |
| work_keys_str_mv | AT yuanzhang shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT yunyunzhou shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT xinluo shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT kaisong shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT xiaotuma shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT adwaitsathe shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT lucgirard shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT guanghuaxiao shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas AT adifgazdar shox2isapotentindependentbiomarkertopredictsurvivalofwhogradeiiiiidiffusegliomas |